Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMAb-1 + DMAb-2
- Development stage
- Unknown
- Lead developer
- Inovio Pharmaceuticals
- Modality
- Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
DMAb-1 + DMAb-2 (also known as INO-A002) is a DNA-encoded monoclonal antibody (DMAb) combination developed by INOVIO Pharmaceuticals in collaboration with The Wistar Institute and AstraZeneca for COVID-19 prophylaxis. Unlike traditional monoclonal antibodies produced in bioreactors, this platform delivers plasmid DNA encoding neutralizing antibodies directly into the patient's skeletal muscle using the CELLECTRA electroporation device. This allows the patient's own cells to serve as a "bioreactor" to produce and secrete functional antibodies (mirroring tixagevimab and cilgavimab) into the bloodstream. The approach aims to provide long-lasting passive immunity with improved scalability and stability compared to protein-based biologics.
- Other names
- DNA-encoded monoclonal antibodiesCOVID-19 DMAbCOVID19 DMAbCOVID 19 DMAb
02
Targets
Omicron RBD (SARS-CoV-2 Omicron spike receptor-binding domain)SARS-CoV-2 spike protein receptor-binding domain Class 1 epitopeSARS-CoV-2 spike protein receptor-binding domain Class 2 epitope
Beyond the preview
Go deeper on DMAb-1 + DMAb-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMAb-1 + DMAb-2.